Logo

American Heart Association

  125
  0


Final ID: MP1229

Post-Impella Creatinine as a Predictor of Length of Stay Outcomes in Patients Undergoing Heart Transplant After Impella 5.5 Support

Abstract Body (Do not enter title and authors here): Background: Renal dysfunction is a known prognostic factor in advanced heart failure and among patients receiving temporary mechanical circulatory support (tMCS). However, the predictive value of post-Impella creatinine in determining healthcare resource utilization in patients bridged to transplant with Impella 5.5 remains unclear. This study aimed to evaluate the association between post-Impella creatinine and key hospitalization metrics in this population.

Methods: We performed a retrospective cohort study of patients who received Impella 5.5 as a bridge-to-transplant between January 2020 and January 2025. Serum creatinine was collected 72 hours after Impella placement. The primary outcome was device-to-discharge time. Secondary outcomes included transplant-to-discharge time, post-transplant ICU length of stay (LOS), and total LOS (admission-discharge). Univariate and multivariable linear regressions were used to examine the association between post-Impella creatinine and each outcome, adjusting for age, gender, BMI, and LVEF.

Results: 133 patients were supported with the Impella 5.5 as BTT and were included (median age 58 years (51–65), 82.7% were male, and 71.4% presented with non-ischemic cardiomyopathy. The median BMI was 27.7 (24.3–32.3), LVEF 17% (15–22), and post-Impella creatinine 1.32 mg/dL (0.96–1.71). The median device-to-discharge time was 45 days (29-64), transplant-to-discharge time was 14 days (12–19), ICU LOS post-transplant was 6 days (4–8), and total LOS was 58 days (42–76). Higher post-Impella creatinine was significantly associated with longer device-to-discharge time (β = 6.67, p = 0.004), longer transplant-to-discharge duration (β = 3.42 p = 0.003), longer ICU LOS (β = 2.19, p = 0.007), and longer total LOS (β = 7.24, p = 0.002) on univariate analysis. Post-impella creatinine remained significantly associated with device-to-discharge time in the multivariate model after adjusting for confounders (β = 6.33, p = 0.006). Importantly, this suggests that patients with lower post-Impella creatinine levels may experience shorter hospitalizations and faster recovery trajectories following transplant.

Conclusions: Post-Impella creatinine is a significant predictor of prolonged hospitalization in patients supported with Impella 5.5 as a bridge to transplant. These findings emphasize the prognostic importance of early renal function assessment and may guide risk stratification and resource planning in advanced heart failure care.
  • Mautong, Hans  ( John H. Stroger Jr. Hospital , Chicago , Illinois , United States )
  • Desai, Aarti  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Alak, çetin  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Wlodkowski, Peter  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Ruiz, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Leoni, Juan  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Nativi-nicolau, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Patel, Parag  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Shapiro, Anna  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Chaudhary, Sanjay  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Goswami, Rohan  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Author Disclosures:
    Hans Mautong: DO NOT have relevant financial relationships | Sanjay Chaudhary: DO NOT have relevant financial relationships | Rohan Goswami: No Answer | Aarti Desai: DO NOT have relevant financial relationships | çetin alak: DO NOT have relevant financial relationships | Peter Wlodkowski: DO NOT have relevant financial relationships | Jose Ruiz: DO NOT have relevant financial relationships | Juan Leoni: DO NOT have relevant financial relationships | Jose Nativi-Nicolau: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Research Funding (PI or named investigator):Natera:Active (exists now) ; Research Funding (PI or named investigator):Alexion:Active (exists now) | Parag Patel: DO NOT have relevant financial relationships | Anna Shapiro: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Pushing the Limits: ECMO, Impella, and the Science Behind Their Power

Sunday, 11/09/2025 , 09:15AM - 10:15AM

Moderated Digital Poster Session

More abstracts on this topic:
4D Cardiac Magnetic Resonance Identifies Differences in Regional Strain Patterns Among Pediatric Heart Transplant Patients with Acute Rejection or Cardiac Allograft Vasculopathy

Henderson Christopher, Starnes Joseph, Samyn Margaret, Damon Bruce, Hernandez Lazaro, Goergen Craig, Soslow Jonathan, Prado Marco Aurélio, Earl Conner, Georgedurrett Kristen, Lee Simon, Nandi Deipanjan, Chan Kak-chen, Shugh Svetlana, Kikano Sandra

A Loss-of-Function Missense Variant in ANGPTL3 Exerts Protective Effects Against Kidney Disease Risk

Zhang David, Ritchie Marylyn, Rader Daniel, Cuchel Marina

More abstracts from these authors:
Variation in Impella 5.5 Support Duration and Ischemic Time Across Donor Transport Technologies

Dadwal Surbhi, Desai Aarti, Ruiz Jose, Shapiro Anna, Goswami Rohan

Support duration as a prognostic indicator in temporary MCS: divergent outcomes based on the 14-day FDA approved duration

Desai Aarti, Patel Parag, Goswami Rohan, Mautong Hans, Dadwal Surbhi, Wlodkowski Peter, Ruiz Jose, Yip Daniel, Lyle Melissa, Leoni Juan, Nativi-nicolau Jose

You have to be authorized to contact abstract author. Please, Login
Not Available